Apollomics GAAP EPS of -$4.04 (NASDAQ:APLM)
Apollomics reported a GAAP EPS of -$4.04 for the first half of 2026, with cash and cash equivalents of $1.0M as of June 30, 2026, according to the company.
Apollomics Inc.
Apollomics is a clinical-stage biopharmaceutical company that discovers and develops oncology therapies, particularly for difficult-to-treat and treatment-resistant cancers. Its biomarker-driven approach screens patients for markers that may indicate they could benefit from targeted therapy. Its pipeline includes tumor inhibitors and immuno-oncology candidates, with three product candidates in active clinical-stage development. Vebreltinib, its most advanced candidate, is an oral c-Met inhibitor being studied for cancers with c-Met alterations. Other candidates include the tumor inhibitor APL-102 and the immuno-oncology products APL-501, APL-502 and APL-801. Apollomics conducts clinical development through its global drug development team in the San Francisco Bay Area and a discovery and development team in Hangzhou, China. It works with partners on some candidates, including APL-502, which is developed by CTTQ in China. The company is headquartered in Foster City, California.
No enriched coverage for $APLM in the last 7 days.
No SEC Form 4 filings for $APLM in the last 30 days.
See all $APLM insider activity →Apollomics reported a GAAP EPS of -$4.04 for the first half of 2026, with cash and cash equivalents of $1.0M as of June 30, 2026, according to the company.
Apollomics (APLM) reported that COO Chen Yi-Kuei's 5,000 restricted stock units vested into 5,000 Class A shares on September 15, 2026, increasing his direct holdings to 20,100 shares. He was also granted an option for 8,000 shares at $23.18 each, vesting in 2027. He indirectly holds 121,248 shares through Maxpro Investment Co.
Apollomics Inc. (APLM) said CEO Hung-Wen Chen bought shares on Aug. 14, 2026, including 166,667 shares at $12 and 103,333 at $15 directly, plus 266,667 at $15 via King Regent Management. Total buys were about $7.55 million, raising direct holdings to 418,334 and indirect to 1,029,695. APLM shares rose to $23.55 Monday.
Recent APLM coverage spans insider activity, financial news and earnings.
Negative earnings and minimal cash raise concerns about liquidity and profitability.
Small insider vesting and option grant; limited dilution and no immediate trading pressure.
Insider buying can support near-term sentiment, but it is not a fundamental catalyst like trial readouts or guidance.
Insider buying at a discount to the current ~$23.55 price can support near-term sentiment, but it is not a fundamental catalyst by itself.
A small capital raise can support liquidity expectations, but dilution risk can cap upside.
AlphAI scores every news story that mentions APLM with an AI model for sentiment and relevance, and aggregates insider trades from Apollomics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Apollomics reported a GAAP EPS of -$4.04 for the first half of 2026, with cash and cash equivalents of $1.0M as of June 30, 2026, according to the company.
Apollomics (APLM) reported that COO Chen Yi-Kuei's 5,000 restricted stock units vested into 5,000 Class A shares on September 15, 2026, increasing his direct holdings to 20,100 shares. He was also granted an option for 8,000 shares at $23.18 each, vesting in 2027. He indirectly holds 121,248 shares through Maxpro Investment Co.
Apollomics Inc. (APLM) said CEO Hung-Wen Chen bought shares on Aug. 14, 2026, including 166,667 shares at $12 and 103,333 at $15 directly, plus 266,667 at $15 via King Regent Management. Total buys were about $7.55 million, raising direct holdings to 418,334 and indirect to 1,029,695. APLM shares rose to $23.55 Monday.
Investing.com reports U.S. insider trades disclosed Monday. Apollomics (APLM) saw CEO Hung-Wen Chen buy about $7.55M and CFO Peter Lin buy $400k. Cardinal Infrastructure (CDNL) had multiple buys totaling about $6.48M. Dyne (DYN), Butterfly Network (BFLY), Kinetik (KNTK), and PBF Energy (PBF) reported large sales.
After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.
Chen Yi-Kuei (Chief Operating Officer) purchased 20,000 indirectly-held shares of Apollomics Inc. (APLM) at $15.00 ($0.30M total) on 2026-08-14.
LIN PETER KUAN-HOW (Chief Financial Officer) purchased 26,667 shares of Apollomics Inc. (APLM) at $15.00 ($0.40M total) on 2026-08-14.
Chen Hung-Wen (Chief Executive Officer) purchased 266,667 indirectly-held shares of Apollomics Inc. (APLM) at $15.00 ($4.00M total) on 2026-08-14.
Chen Hung-Wen (Chief Executive Officer) purchased 270,000 shares of Apollomics Inc. (APLM) at an average of $13.15 ($12.00–$15.00, $3.55M total) across 2 trades on 2026-08-14.
Apollomics Inc. (APLM) said it entered definitive subscription agreements for a roughly $10 million private placement. It includes cash subscriptions for 533,334 Class A shares at $15.00 (about $8.0 million) and conversion of a $2 million unsecured convertible note into 166,667 shares at $12.00. Closing is expected around Aug. 14, 2026. APLM shares were $18.16 Tuesday.